Total Payments
$308,793
2024 Payments
$56,984
Companies
24
Transactions
545
Medicare Patients
2,712
Medicare Billing
$404,133
Payment Breakdown by Category
Other$224,714 (72.8%)
Travel$37,038 (12.0%)
Consulting$35,913 (11.6%)
Food & Beverage$10,861 (3.5%)
Education$266.42 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $224,714 | 96 | 72.8% |
| Travel and Lodging | $37,038 | 134 | 12.0% |
| Consulting Fee | $35,913 | 24 | 11.6% |
| Food and Beverage | $10,861 | 285 | 3.5% |
| Education | $266.42 | 6 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $151,782 | 220 | $0 (2024) |
| SANOFI PASTEUR INC. | $96,785 | 104 | $0 (2023) |
| Insmed, Inc. | $34,928 | 54 | $0 (2024) |
| ABBVIE INC. | $19,359 | 42 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $3,932 | 30 | $0 (2021) |
| Janssen Biotech, Inc. | $678.98 | 43 | $0 (2021) |
| ViiV Healthcare Company | $350.97 | 18 | $0 (2022) |
| Smith+Nephew, Inc. | $151.32 | 3 | $0 (2019) |
| Janssen Products, LP | $130.47 | 3 | $0 (2021) |
| Hollister Incorporated | $112.00 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $56,984 | 71 | Gilead Sciences, Inc. ($52,086) |
| 2023 | $55,134 | 64 | Gilead Sciences, Inc. ($27,672) |
| 2022 | $46,939 | 53 | SANOFI PASTEUR INC. ($20,058) |
| 2021 | $19,804 | 64 | Gilead Sciences, Inc. ($8,013) |
| 2020 | $29,445 | 43 | SANOFI PASTEUR INC. ($21,807) |
| 2019 | $78,690 | 135 | SANOFI PASTEUR INC. ($41,671) |
| 2018 | $16,403 | 54 | Gilead Sciences, Inc. ($15,929) |
| 2017 | $5,394 | 61 | Gilead Sciences Inc ($4,364) |
All Payment Transactions
545 individual payment records from CMS Open Payments — Page 1 of 22
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | Insmed, Inc. | Arikayce (Drug) | Food and Beverage | In-kind items and services | $31.92 | General |
| Category: Respiratory | ||||||
| 11/21/2024 | Gilead Sciences, Inc. | Veklury (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $540.00 | General |
| Category: COVID-19 | ||||||
| 10/21/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $8.76 | General |
| 09/23/2024 | Gilead Sciences, Inc. | Descovy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,190.00 | General |
| Category: HIV | ||||||
| 09/18/2024 | Gilead Sciences, Inc. | Descovy (Drug) | Travel and Lodging | In-kind items and services | $956.64 | General |
| Category: HIV | ||||||
| 09/18/2024 | Gilead Sciences, Inc. | Veklury (Drug) | Travel and Lodging | In-kind items and services | $96.17 | General |
| Category: COVID-19 | ||||||
| 09/18/2024 | Gilead Sciences, Inc. | Descovy (Drug) | Food and Beverage | In-kind items and services | $91.44 | General |
| Category: HIV | ||||||
| 09/18/2024 | Gilead Sciences, Inc. | Veklury (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: COVID-19 | ||||||
| 09/18/2024 | Gilead Sciences, Inc. | Veklury (Drug) | Food and Beverage | In-kind items and services | $18.18 | General |
| Category: COVID-19 | ||||||
| 09/06/2024 | Gilead Sciences, Inc. | Biktarvy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $490.00 | General |
| Category: HIV | ||||||
| 08/07/2024 | Gilead Sciences, Inc. | Descovy (Drug) | Food and Beverage | In-kind items and services | $45.16 | General |
| Category: HIV | ||||||
| 08/07/2024 | Gilead Sciences, Inc. | Descovy (Drug) | Food and Beverage | In-kind items and services | $45.14 | General |
| Category: HIV | ||||||
| 08/07/2024 | Gilead Sciences, Inc. | Descovy (Drug) | Food and Beverage | In-kind items and services | $32.22 | General |
| Category: HIV | ||||||
| 08/07/2024 | Gilead Sciences, Inc. | Descovy (Drug) | Travel and Lodging | In-kind items and services | $21.09 | General |
| Category: HIV | ||||||
| 07/24/2024 | Gilead Sciences, Inc. | Veklury (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,040.00 | General |
| Category: COVID-19 | ||||||
| 07/22/2024 | Gilead Sciences, Inc. | Descovy (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,170.00 | General |
| Category: HIV | ||||||
| 07/19/2024 | MIMEDX Group, Inc. | — | Food and Beverage | In-kind items and services | $26.53 | General |
| 07/17/2024 | Gilead Sciences, Inc. | Descovy (Drug) | Travel and Lodging | In-kind items and services | $1,059.55 | General |
| Category: HIV | ||||||
| 07/17/2024 | Gilead Sciences, Inc. | Descovy (Drug) | Travel and Lodging | In-kind items and services | $528.67 | General |
| Category: HIV | ||||||
| 07/17/2024 | Gilead Sciences, Inc. | Descovy (Drug) | Travel and Lodging | In-kind items and services | $455.62 | General |
| Category: HIV | ||||||
| 07/09/2024 | ABBVIE INC. | DALVANCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,250.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 07/01/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $19.94 | General |
| 06/30/2024 | Gilead Sciences, Inc. | Veklury (Drug) | Travel and Lodging | In-kind items and services | $427.08 | General |
| Category: COVID-19 | ||||||
| 06/30/2024 | Gilead Sciences, Inc. | Veklury (Drug) | Travel and Lodging | In-kind items and services | $404.04 | General |
| Category: COVID-19 | ||||||
| 06/30/2024 | Gilead Sciences, Inc. | Veklury (Drug) | Travel and Lodging | In-kind items and services | $89.04 | General |
| Category: COVID-19 | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 11 | 578 | 1,011 | $318,476 | $81,378 |
| 2022 | 14 | 704 | 1,198 | $358,228 | $90,608 |
| 2021 | 12 | 750 | 1,210 | $381,578 | $110,592 |
| 2020 | 10 | 680 | 1,173 | $400,457 | $121,556 |
Total Patients
2,712
Total Services
4,592
Medicare Billing
$404,133
Procedure Codes
53
All Medicare Procedures & Services
53 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 171 | 434 | $91,140 | $27,555 | 30.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 116 | 129 | $74,175 | $17,964 | 24.2% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 85 | 91 | $36,400 | $9,481 | 26.0% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 67 | 98 | $31,753 | $9,365 | 29.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 20 | 25 | $13,125 | $3,532 | 26.9% |
| 11042 | Removal of skin and tissue, 20.0 sq cm or less | Facility | 2023 | 17 | 74 | $21,830 | $3,426 | 15.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 18 | 48 | $14,400 | $2,449 | 17.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 11 | 11 | $6,927 | $1,960 | 28.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 17 | 17 | $7,140 | $1,646 | 23.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 13 | 18 | $7,560 | $1,396 | 18.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 15 | 17 | $5,100 | $1,251 | 24.5% |
| 97597 | Removal of tissue from wound, 20.0 sq cm or less | Facility | 2023 | 13 | 29 | $5,626 | $792.61 | 14.1% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2023 | 15 | 20 | $3,300 | $560.60 | 17.0% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 106 | 116 | $66,700 | $18,561 | 27.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 122 | 290 | $60,900 | $16,476 | 27.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 81 | 175 | $56,700 | $14,414 | 25.4% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 120 | 128 | $38,400 | $10,276 | 26.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 23 | 36 | $18,675 | $5,153 | 27.6% |
| 11042 | Removal of skin and tissue, 20.0 sq cm or less | Facility | 2022 | 27 | 98 | $28,910 | $4,740 | 16.4% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 58 | 144 | $18,144 | $4,549 | 25.1% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 39 | 40 | $16,000 | $4,350 | 27.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 15 | 15 | $9,375 | $2,738 | 29.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 22 | 26 | $10,580 | $2,581 | 24.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 27 | 42 | $12,150 | $2,205 | 18.1% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 13 | 15 | $4,950 | $1,594 | 32.2% |
About Dr. Peter Sebeny, M.D
Dr. Peter Sebeny, M.D is a Infectious Disease healthcare provider based in Newburyport, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/11/2006. The National Provider Identifier (NPI) number assigned to this provider is 1194704932.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Peter Sebeny, M.D has received a total of $308,793 in payments from pharmaceutical and medical device companies, with $56,984 received in 2024. These payments were reported across 545 transactions from 24 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($224,714).
As a Medicare-enrolled provider, Sebeny has provided services to 2,712 Medicare beneficiaries, totaling 4,592 services with total Medicare billing of $404,133. Data is available for 4 years (2020–2023), covering 53 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Newburyport, MA
- Active Since 01/11/2006
- Last Updated 06/16/2021
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1194704932
Products in Payments
- Descovy (Drug) $69,293
- FLUZONE HIGH-DOSE (Biological) $39,815
- Arikayce (Drug) $34,896
- FLUZONE HIGH-DOSE (Drug) $34,296
- Veklury (Drug) $33,812
- Truvada (Drug) $21,592
- DALVANCE (Drug) $19,339
- FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE (Biological) $9,756
- MENQUADFI (Biological) $5,524
- Biktarvy (Drug) $1,790
- PREZCOBIX (Drug) $485.76
- DOVATO (Drug) $212.69
- Symtuza (Drug) $202.63
- FLUBLOK QUADRIVALENT (Drug) $172.65
- NO PRODUCT DISCUSSED (Drug) $145.01
- DIFICID (Drug) $122.18
- SYMTUZA (Drug) $121.06
- ENDOFORM (Device) $112.00
- PICO (Device) $110.88
- FLUZONE QUADRIVALENT (Drug) $99.77
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.